Rheumatoid arthritis (RA) is the most prevalent inflammatory rheumatic disorder. It is a chronic and incurable disease that leads to painful in- and international expert recommendations and practice guidelines. Numerous non-systematic reviews are found and analysed for additional sources of information that is not identified through the systematic search. Case reports and safety assessements are considered as well. A total of 137 publications is included. The primary outcome measures in clinical trials are suppression of inflammatory disease activity and slowing of structural joint damage. Clinical response is usually measured by standardised response criteria that allow a semi-quantitative classification of improvement from baseline by 20%, 50%, or 70%.
Results
Health Technology Assessment reports and metaanalyses cannot be identified. A total of 12 clinical trials are analysed, as well as national Wallnöfer-Zentrum I, Hall in Tirol, Österreich 5 Universität Duisburg-Essen, Lehrstuhl für Medizinmanagement, DuisburgEssen, Deutschland and international expert recommendations and practice guidelines. Numerous non-systematic reviews are found and analysed for additional sources of information that is not identified through the systematic search. Case reports and safety assessements are considered as well.
A total of 137 publications is included. The primary outcome measures in clinical trials are suppression of inflammatory disease activity and slowing of structural joint damage. Clinical response is usually measured by standardised response criteria that allow a semi-quantitative classification of improvement from baseline by 20%, 50%, or 70%.
In patients with RA refractory to conventional treatment, TNF-α-antagonists are unequivocally superior to Methotrexate with regard to disease activity, functional status and prevention of structural damage. In patients with early RA, TNF-α-antagonists show a more rapid onset of antiinflammatory effects than Methotrexate. However, differences in clinical response rates and radiologic progression disappear after a few months of treatment and are no longer statistically significant. Serious adverse events are rare in clinical trials and do not occur significantly more often than in the control groups. However, case reports and surveillance registries show an increased risk for serious infectious complications, particularly tuberculosis. Expert panels recommend the use of TNF-α-antagonists in patients with active refractory RA after failure of conventional treatment. Studies that compare Infliximab and Etanercept are lacking.
There are no pharmacoeconomic studies although decision analytic models of TNF-α-antagonists for the treatment of RA exist. Based on the results of the models, a combination therapy with Hydroxychloroquin (HCQ), Sulfaslazin (SASP) and Methotrexate as well as Etanercept/Methotrexate can be considered a cost-effective treatment for Methotrexateresistant RA.
Conclusions
TNF-α-antagonists are clearly effective in RA patients with no or incomplete response to Methotrexate and superior to continuous use of Methotrexate. It refers to both, reduction of inflammatory disease activity including pain relief and improved functional status, and prevention of structural joint damage. Therefore, TNF-α-antagonism is an important new approach in the treatment of RA. There is still insufficient evidence that early use of TNF-α-antagonists in RA prior to standard agents is beneficial and further studies have to be awaited. An analytic model suggests that TNF-α-antagonists are, due to their clinical effectiveness in patients with no or incomplete response to Methotrexate, a cost-effective alternative to common therapies chosen in the subpopulations of patients. Nevertheless, it has to be borne in mind that the acquisition costs of TNF-α-antagonists lead to high incremental costs and C/E ratios, which exceed the common frame of assessing the cost-effectiveness of medical methods and technologies. Hence, society's willingness-to-pay is the critical determinant in the question whether TNF-α-antagonists shall be reimbursed or not, or to define criteria for reimbursement. Changes in the quality of life attributable to the use of TNF-α-antagonists in RA have not yet been assessed which might assist the decision making.
With respect of the questions mentioned above and the potential financial effect of a systematic use of TNF-α-antagonists in the treatment of RA, we come to the conclusion that TNF-α-antagonists should not introduced as a standard benefit reimbursed by the statutory health insurers in Germany. From the social as well as from the individual perspective RA is a substantial financial burden. Especially the high rates of indirect and intangible costs of RA are of major concern when assessing the health economic consequences of RA. A major proportion of the direct costs is caused by secondary care whereas the costs for medication account only for 15% of the total costs. To date biologicals play an inferior role in treating RA in Germany.
From the health economic perspective the cost-effectiveness of biologicals is examined and the circumstances are to be assessed under which biologicals can be considered cost-effective. Hence, further health economic research needs are assessed.
Methods
The portion of the population of concern in the report are adult patients. In order to assess available evidence a systematic search in scientific databases and in relevant journals has been conducted. This assessment was complemented by a handsearch in relevant journals and on the manufactures`internet pages. The available information was assessed by using established evidencemedicine based criteria and the checklists prepared by the German Scientific Working Group for Technology Assessment in Health Care. The health economic consequences of the treatment of RA with TNF-α-antagonists were assessed in a systematic search in health economic databases (DARE, EMBASE, NEED, and MEDLINE) and an extensive handsearch in health economic journals. International HTA-institutions were contacted in order to identify relevant information. Publications had be written in German, English and French.
Results
Neither HTA reports nor meta-studies could be identified. Twelve clinical studies were found and analysed. National and international guidelines, expert options, non-systematic reviews, case reports and publications concerning the safety of TNF-α-antagonists where included in the assessment of the clinical effectiveness. 137 publications were identified. The primary clinical goal of assessing TNF-α-antagonists in the treatment of RA was the suppression of the clinical activity and a delay of the destruction of RA-affected joints. Clinical response was assessed using standardized response criteria on the basis of semi-quantative instruments using 20%, 50% or 70% improvement levels.
In patients with refractive RA TNF-α-antagonists are significantly more effective than methotrexate in the reduction of symptoms, in stabilising functionality and quality of life as well as structural destruction of the joints. The faster onset of clinical response using TNF-α-antagonists compared with methotrexate can be observed. Nevertheless the clinical response and the inhibition of progression radiologic lesions equal within several months. Severe complications of TNF-α-antagonists are rare and their rate does not differ significantly between groups. Case studies describe the risk of severe infections, especially tuberculosis. Therapeutic guidelines and expert options suggest TNF-α-antagonists in the treatment of patients with refractive RA after insufficient response to standard therapy. No head-to-head-studies between infliximab and etanercept exist to date. Apart from analytic decision models health economic studies assess the cost-effectiveness of which TNF-α-antagonists are lacking. Based on decision models it can be concluded that a combination therapy of hydroxychloroquin (HCQ), sulfasalazin (SASP) and methotrexate as well as a combination of etanercept and methotrexate can be considered cost-effective in principal.
Conclusion
TNF-α-antagonists are effective in patients with insufficient response to a standard therapy with methotrexte. In those patients TNF-α-antagonists are significantly more effective compared to the standard therapy. This applies to lowering the inflammation activity as well as to pain relief, improvement of functionality and slowing down joint destruction.
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